IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Cambrex Buys Estonian Firm

12:58 PM MST | January 18, 2008 | Alex Scott

Cambrex says that its Cambrex Karlskoga (Karlskoga, Sweden) subsidiary has agreed to acquire privately owned active pharmaceutical ingredients (API) R&D company ProSyntest (Tallinn, Estonia). Financial terms were not disclosed. ProSyntest, spun out of Tallinn University of Technology (Tallinn) in 1990, employs 25 chemists. The company’s activities include process development, and expertise in chiral chemistries. The acquisition “will enable Cambrex to more effectively compete in the high-growth, early clinical-stage pharmaceutical custom...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers




contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa